Successful liver transplantation and long-term follow-up in a patient with MPI-CDG

Pediatrics. 2014 Jul;134(1):e279-83. doi: 10.1542/peds.2013-2732.

Abstract

Hepatopathy is the most common feature in the Congenital Disorders of Glycosylation (CDG). More than 70 subtypes have been identified in this growing group of inborn errors. Most defects present as multisystem disease, whereas phosphomannose isomerase deficiency (MPI-CDG) presents with exclusive hepato-intestinal phenotype. MPI-CDG has been considered as one of the very few treatable disorders of glycosylation; several patients showed significant improvement of their life-threatening protein-losing enteropathy and coagulation disorder on oral mannose supplementation therapy. However, patients who have MPI-CDG develop progressive liver insufficiency during a later course of disease. A patient who had MPI-CDG developed progressive liver fibrosis, despite oral mannose supplementation and repeated fractionated heparin therapy. She showed mannose therapy-associated hemolytic jaundice. She developed severe dyspnea and exercise intolerance owing to pulmonary involvement, necessitating liver transplant. After transplantation her physical exercise tolerance, pulmonary functions, and metabolic parameters became fully restored. She is still doing well 2 years after transplantation now. In conclusion, we here report on the first successful liver transplantation in CDG.

Keywords: MPI-CDG; congenital disorder of glycosylation; liver transplantation.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Child, Preschool
  • Congenital Disorders of Glycosylation / surgery*
  • Female
  • Follow-Up Studies
  • Humans
  • Liver Transplantation*
  • Mannose-6-Phosphate Isomerase / deficiency*
  • Remission Induction
  • Time Factors

Substances

  • Mannose-6-Phosphate Isomerase